LMAT LEMAITRE VASCULAR INCcompanySEC Filings & Insider Trading Activity 2026
Latest LEMAITRE VASCULAR INC (LMAT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 7, 2025, an 8-K current report filed on April 14, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for LEMAITRE VASCULAR INC (LMAT) (SEC CIK 1158895), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: global medical devices and human tissue cryopreservation services focused on treating peripheral vascular, end-stage renal, and cardiovascular diseases
- • New product emphasis: launch of PhasTIPP Powered Phlebectomy System in US (H1 2024) and marketing of Artegraft biologic graft in EU after April 2025 CE mark approval
Risk Factors
- • Regulatory risk: ASC 606 revenue recognition standard requires judgment in estimating sales returns, impacting reported revenue and allowances
- • Macroeconomic threat: $9.1 million inventory purchase commitments expose business to supply cost fluctuations through 2026
Management Discussion & Analysis
- • Revenue $249.6M in 2025, up 14% YoY (+$29.7M from $219.9M in 2024) with highest growth in EMEA (+22%, +$13.2M)
- • Gross margin 71.5% in 2025 vs 68.6% in 2024, up 290bps; driven by Employee Retention Credit, manufacturing efficiencies, and price increases
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • New product recall risk triggered by April 2025 inadequate seal issue on TufTex, Pruitt Occlusion, and Pruitt Irrigation catheters packaging
- • Updated regulatory risk: August 2025 FDA warning letter to Artegraft facility, no material financial impact or sales disruption reported
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q-period earnings disclosure — full financial results and commentary contained in the referenced press release exhibit (Exhibit 99.1)
- • LMAT is a vascular surgery device company; earnings reports typically cover revenue, gross margin, and guidance updates material to investors
Annual Reports Archive10-K
AI-powered analysis of LEMAITRE VASCULAR INC (LMAT) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of LEMAITRE VASCULAR INC (LMAT) 10-Q quarterly reports filed with SEC EDGAR.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of LEMAITRE VASCULAR INC (LMAT) 8-K current reports disclosing material events.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $161.7M | $193.5M | $219.9M | $249.6M |
| Gross Profit | $104.9M | $127.0M | $150.9M | $178.5M |
| Operating Income | — | $36.7M | $52.3M | $67.9M |
| Net Income | — | $30.1M | $44.0M | $57.7M |
| Gross Margin | 64.9% | 65.7% | 68.6% | 71.5% |
| Op. Margin | — | 19.0% | 23.8% | 27.2% |
| Net Margin | — | 15.6% | 20.0% | 23.1% |
| Balance Sheet | ||||
| Total Assets | — | $346.8M | $551.8M | $615.7M |
| Equity | — | $297.9M | $337.3M | $393.5M |
| ROE | — | 10.1% | 13.1% | 14.7% |
Source: XBRL financial data from LEMAITRE VASCULAR INC (LMAT) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 14, 2026 | — | — | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 25, 2026 | — | Analysis | — |
10-Q | Nov 7, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Feb 28, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 8, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 10, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Mar 1, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 5, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-K | Feb 28, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 10, 2021 | Mar 31, 2021 | — | |
10-K | Mar 12, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 6, 2020 | Sep 30, 2020 | — | |
10-Q | Aug 6, 2020 | Jun 30, 2020 | — |
Frequently Asked Questions
What are the latest LMAT SEC filings in 2026?
LEMAITRE VASCULAR INC (LMAT) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 7, 2025, an 8-K current report on April 14, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did LMAT file its most recent 10-K annual report?
LEMAITRE VASCULAR INC (LMAT) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view LMAT 10-Q quarterly reports?
LEMAITRE VASCULAR INC (LMAT)'s most recent 10-Q quarterly report was filed on November 7, 2025. SignalX displays every LMAT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has LMAT filed recently?
LEMAITRE VASCULAR INC (LMAT)'s most recent 8-K was filed on April 14, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find LMAT insider trading activity (Form 4)?
SignalX aggregates every LMAT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does LMAT file with the SEC?
LEMAITRE VASCULAR INC (LMAT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LMAT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for LEMAITRE VASCULAR INC (LMAT).
What is LMAT's SEC CIK number?
LEMAITRE VASCULAR INC (LMAT)'s SEC CIK (Central Index Key) number is 1158895. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1158895 to look up all LMAT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find LMAT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from LEMAITRE VASCULAR INC (LMAT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of LEMAITRE VASCULAR INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 42+ filings.